References
Bading-Taïka, B., Akinyeke, T., Alcázar, M., Choi, J., Ouanesisouk, M., Torres, E., & Stevens, J. (2018). Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice. Journal of Food Bioactives, 111–123. https://doi.org/10.31665/jfb.2018.3154
Bouso, J., FornÃs, I., Ventura, M., Loenen, B., Sainz-Cort, A., Jiménez-Garrido, D., & Jenks, C. (2020). An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers. Archives of Clinical Psychiatry (São Paulo), 47(2), 51–54. https://doi.org/10.1590/0101-60830000000231
Brunt, T. (2026). Rare but relevant: Ibogaine and cardiovascular complications—Prolonged QT interval and ventricular arrhythmias. Addiction. https://doi.org/10.1111/add.70319
Canadian Institute for Substance Use Research. (2026, March 3). Substance use costs in Canada in 2020. University of Victoria. http://csuch.ca/substance-use-costs/current-costs/
Cherian, K., Shinozuka, K. B., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic therapy: A primer for primary care clinicians—Ibogaine. American Journal of Therapeutics, 31(2), e133–e140.
Fountaine, C., L’Heureux, A., & Erny, T. (2025). Ibogaine. In Oxford textbook of psychedelic medicine (pp. 124–137). Oxford University Press. https://doi.org/10.1093/med/9780197760864.003.0008
Glick, S., & Maisonneuve, I. (2000). Development of novel medications for drug addiction: The legacy of an African shrub. Annals of the New York Academy of Sciences, 909(1), 88–103. https://doi.org/10.1111/j.1749-6632.2000.tb06677.x
Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680–687. https://doi.org/10.1002/jcph.471
Henriques, G., Anjos-Santos, A., Rodrigues, I., Nascimento-Rocha, V., Reis, H., Libarino-Santos, M., & Berro, L. (2021). Ibogaine blocks cue- and drug-induced reinstatement of conditioned place preference to ethanol in male mice. Frontiers in Pharmacology, 12, Article 739012. https://doi.org/10.3389/fphar.2021.739012
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Oosteren, T., Kramers, C., & Verkes, R. (2021). Safety of ibogaine administration in detoxification of opioid-dependent individuals: A descriptive open-label observational study. Addiction, 117(1), 118–128. https://doi.org/10.1111/add.15448
Köck, P., et al. (2022). A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment, 138, 108717. https://doi.org/10.1016/j.jsat.2022.108717
Leal, M., Souza, D., & Elisabetsky, E. (2000). Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochemical Research, 25(8), 1083–1087. https://doi.org/10.1023/a:1007665911622
Marton, S., González, B., RodrÃguez, S., Miquel, E., Palma, L., Pazos, M., & Carrera, I. (2018). Ibogaine modifies GDNF, BDNF and NGF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. ChemRxiv. https://doi.org/10.26434/chemrxiv.7261559.v1
Mash, D., & Karukin, M. (2023). Ibogaine and noribogaine. In The Oxford handbook of psychedelic medicine (pp. 419–440). Oxford University Press. https://doi.org/10.1093/oxfordhb/9780197618431.013.16
Mash, D., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 9, Article 529. https://doi.org/10.3389/fphar.2018.00529
Mboukoaabo, C. (2024). L’iboga: Un patrimoine naturel, culturel et national au service du monde. RSSI. https://doi.org/10.61585/pud-ebad-rssi-v1n106
Mosca, A., Chiappini, S., Miuli, A., Mancusi, G., Santovito, M. C., Di Carlo, F., Pettorruso, M., Corkery, J. M., Canessa, C., Martinotti, G., & Di Giannantonio, M. (2023). Ibogaine/noribogaine in the treatment of substance use disorders: A systematic review of the current literature. Current Neuropharmacology, 21(11), 2178–2194. https://doi.org/10.2174/1570159X21666221017085612
Pulido-Saavedra, A., Oliva, H., Prudente, T., Kitaneh, R., Nunes, E., Fogg, C., & Angarita, G. (2025). Effects of psychedelics on opioid use disorder: A scoping review of preclinical studies. Cellular and Molecular Life Sciences, 82(1). https://doi.org/10.1007/s00018-024-05519-2
Rangari, S., Rane, B., Baviskar, S., Khatic, S., Jain, J., & Sonwane, M. (2015). Thin layer chromatography of ibogaine from plant extract of Tabernanthe iboga. Journal of Current Pharma Research, 5(3), 1565–1568.
Rodger, J. (2011). The visionary cure of the addiction war? Ibogaine: Social context, subcultural identity, and implications for drug policy. Drugs and Alcohol Today, 11(2), 77–89. https://doi.org/10.1108/17459261111174037
Rodger, J. (2018). Understanding the healing potential of ibogaine through a comparative and interpretive phenomenology of the visionary experience. Anthropology of Consciousness, 29(1), 77–119. https://doi.org/10.1111/anoc.12088
Wasko, M., Witt-Enderby, P., & Surratt, C. (2018). DARK classics in chemical neuroscience: Ibogaine. ACS Chemical Neuroscience, 9(10), 2475–2483. https://doi.org/10.1021/acschemneuro.8b00294
Wilson, C., Millar, T., & Matieschyn, Z. (2021). Novel treatment of opioid use disorder using ibogaine and iboga in two adults. Journal of Psychedelic Studies, 4(3), 149–155. https://doi.org/10.1556/2054.2020.00133
Zúbaran, C. (2000). Ibogaine and noribogaine: Comparing parent compound to metabolite. CNS Drug Reviews, 6(3), 219–240. https://doi.org/10.1111/j.1527-3458.2000.tb00149.x
Home » Content » PAT 502 Purple Group Ibogaine Video Project
PAT 502 Purple Group Ibogaine Video Project
References
Bading-Taïka, B., Akinyeke, T., Alcázar, M., Choi, J., Ouanesisouk, M., Torres, E., & Stevens, J. (2018). Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice. Journal of Food Bioactives, 111–123. https://doi.org/10.31665/jfb.2018.3154
Bouso, J., FornÃs, I., Ventura, M., Loenen, B., Sainz-Cort, A., Jiménez-Garrido, D., & Jenks, C. (2020). An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers. Archives of Clinical Psychiatry (São Paulo), 47(2), 51–54. https://doi.org/10.1590/0101-60830000000231
Brunt, T. (2026). Rare but relevant: Ibogaine and cardiovascular complications—Prolonged QT interval and ventricular arrhythmias. Addiction. https://doi.org/10.1111/add.70319
Canadian Institute for Substance Use Research. (2026, March 3). Substance use costs in Canada in 2020. University of Victoria. http://csuch.ca/substance-use-costs/current-costs/
Cherian, K., Shinozuka, K. B., Tabaac, B. J., Arenas, A., Beutler, B. D., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic therapy: A primer for primary care clinicians—Ibogaine. American Journal of Therapeutics, 31(2), e133–e140.
Fountaine, C., L’Heureux, A., & Erny, T. (2025). Ibogaine. In Oxford textbook of psychedelic medicine (pp. 124–137). Oxford University Press. https://doi.org/10.1093/med/9780197760864.003.0008
Glick, S., & Maisonneuve, I. (2000). Development of novel medications for drug addiction: The legacy of an African shrub. Annals of the New York Academy of Sciences, 909(1), 88–103. https://doi.org/10.1111/j.1749-6632.2000.tb06677.x
Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680–687. https://doi.org/10.1002/jcph.471
Henriques, G., Anjos-Santos, A., Rodrigues, I., Nascimento-Rocha, V., Reis, H., Libarino-Santos, M., & Berro, L. (2021). Ibogaine blocks cue- and drug-induced reinstatement of conditioned place preference to ethanol in male mice. Frontiers in Pharmacology, 12, Article 739012. https://doi.org/10.3389/fphar.2021.739012
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Oosteren, T., Kramers, C., & Verkes, R. (2021). Safety of ibogaine administration in detoxification of opioid-dependent individuals: A descriptive open-label observational study. Addiction, 117(1), 118–128. https://doi.org/10.1111/add.15448
Köck, P., et al. (2022). A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment, 138, 108717. https://doi.org/10.1016/j.jsat.2022.108717
Leal, M., Souza, D., & Elisabetsky, E. (2000). Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochemical Research, 25(8), 1083–1087. https://doi.org/10.1023/a:1007665911622
Marton, S., González, B., RodrÃguez, S., Miquel, E., Palma, L., Pazos, M., & Carrera, I. (2018). Ibogaine modifies GDNF, BDNF and NGF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. ChemRxiv. https://doi.org/10.26434/chemrxiv.7261559.v1
Mash, D., & Karukin, M. (2023). Ibogaine and noribogaine. In The Oxford handbook of psychedelic medicine (pp. 419–440). Oxford University Press. https://doi.org/10.1093/oxfordhb/9780197618431.013.16
Mash, D., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology, 9, Article 529. https://doi.org/10.3389/fphar.2018.00529
Mboukoaabo, C. (2024). L’iboga: Un patrimoine naturel, culturel et national au service du monde. RSSI. https://doi.org/10.61585/pud-ebad-rssi-v1n106
Mosca, A., Chiappini, S., Miuli, A., Mancusi, G., Santovito, M. C., Di Carlo, F., Pettorruso, M., Corkery, J. M., Canessa, C., Martinotti, G., & Di Giannantonio, M. (2023). Ibogaine/noribogaine in the treatment of substance use disorders: A systematic review of the current literature. Current Neuropharmacology, 21(11), 2178–2194. https://doi.org/10.2174/1570159X21666221017085612
Pulido-Saavedra, A., Oliva, H., Prudente, T., Kitaneh, R., Nunes, E., Fogg, C., & Angarita, G. (2025). Effects of psychedelics on opioid use disorder: A scoping review of preclinical studies. Cellular and Molecular Life Sciences, 82(1). https://doi.org/10.1007/s00018-024-05519-2
Rangari, S., Rane, B., Baviskar, S., Khatic, S., Jain, J., & Sonwane, M. (2015). Thin layer chromatography of ibogaine from plant extract of Tabernanthe iboga. Journal of Current Pharma Research, 5(3), 1565–1568.
Rodger, J. (2011). The visionary cure of the addiction war? Ibogaine: Social context, subcultural identity, and implications for drug policy. Drugs and Alcohol Today, 11(2), 77–89. https://doi.org/10.1108/17459261111174037
Rodger, J. (2018). Understanding the healing potential of ibogaine through a comparative and interpretive phenomenology of the visionary experience. Anthropology of Consciousness, 29(1), 77–119. https://doi.org/10.1111/anoc.12088
Wasko, M., Witt-Enderby, P., & Surratt, C. (2018). DARK classics in chemical neuroscience: Ibogaine. ACS Chemical Neuroscience, 9(10), 2475–2483. https://doi.org/10.1021/acschemneuro.8b00294
Wilson, C., Millar, T., & Matieschyn, Z. (2021). Novel treatment of opioid use disorder using ibogaine and iboga in two adults. Journal of Psychedelic Studies, 4(3), 149–155. https://doi.org/10.1556/2054.2020.00133
Zúbaran, C. (2000). Ibogaine and noribogaine: Comparing parent compound to metabolite. CNS Drug Reviews, 6(3), 219–240. https://doi.org/10.1111/j.1527-3458.2000.tb00149.x